MedBodh Clinical & Health Services | Editorial coverage: 25 October 2026
Amikacin is an aminoglycoside used for selected serious bacterial infections, usually guided by microbiology and local antimicrobial policy.
Quick Note Sheet
- Category: Drug guide
- Topic: Amikacin Injection: Weight-Based Dose, Renal Adjustment and Ototoxicity Monitoring
- Key principle: verify the original source and patient-specific or institution-specific requirements.
- Scope: clinician education and safe operational practice.
Core dose principle
The referenced US label describes 15 mg/kg/day in two or three divided doses for adults and older infants with normal renal function, with a maximum of 1.5 g/day. This is not a universal once-daily regimen and does not override local infection-specific protocols. For neonates, the label describes an initial 10 mg/kg followed by 7.5 mg/kg every 12 hours; specialist neonatal guidance is essential.
Why renal function matters
Amikacin is cleared mainly through the kidneys. Impaired renal function prolongs exposure and raises nephrotoxicity and ototoxicity risk. Obtain baseline weight, serum creatinine and estimated renal function; reassess during treatment.
Therapeutic drug monitoring
The cited label advises serum levels where feasible and cautions against prolonged peak levels above 35 mcg/mL and troughs above 10 mcg/mL in its conventional dosing framework. Modern extended-interval protocols use different sampling and targets; never apply conventional peak/trough limits indiscriminately.
Administration and safety
Check product strength and manufacturer instructions before IV dilution or infusion. Avoid preventable co-exposure to other nephrotoxic or ototoxic medicines where possible. Monitor urine output, renal function, hearing symptoms, tinnitus, vertigo and neuromuscular effects.
Clinical checklist
Confirm organism susceptibility, dosing weight, renal function, chosen dosing strategy, serum-level schedule, treatment duration and planned antibiotic review.
Practical safety summary
| Before action | Confirm |
|---|---|
| Source | Current original label, official notice or institutional SOP |
| Applicability | Correct patient, course, service, route or programme |
| Safety | Contraindications, eligibility, documentation and follow-up |
| Communication | Record decisions and clarify discrepancies with the responsible authority |
Frequently asked questions
Can this article replace the official source?
No. It is a MedBodh educational interpretation. Follow the complete official document and locally applicable instructions.
Are all institutions and patients covered by one rule?
No. Product labels, clinical indications, patient characteristics and administrative instructions differ.
Primary reference
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=840ba25a-d60c-4f0d-a084-71b0c68237df
Editorial safety notice: This article does not establish a new government order or universal treatment protocol. Verify updates before acting.